People are talking about Osiris Therapeutics (OSIR) as a potential biotech stock for investment. Here is a blog post I did about the company and its estimated market for the drug in 2010. By the way, as a company with a high R and D costs and the big product in the future, it has an astoundingly high PE ration - PE (forward) 94.74.
235 Million Market for Prochymal estimated for 2017
Here
is another post about some controversy over how they are running the
double blind studies. Patients who assume they got the placebo are
asking for the actual drug.
Is the FDA Killing Crohn's Patients?
Here is a quote from Zacks.com.
Here Come the Stem Cells
Finding the next big thing is certainly something biotech investors are always in searching for. Above we discussed our enthusiasm for antisense technology as powerful drug discovery engine. Perhaps the only other discovery platform that provides as much enthusiasm as antisense is stem cells. The leading stem cell company is Osiris Therapeutics (OSIR).
Osiris is developing Prochymal, an adult stem cell product currently in 3 phase III trials for steroid refractory graft-vs-host disease (GvHD), acute GvHD and Crohn’s disease. Prochymal is also in a slew of earlier-stage clinical programs for diabetes, myocardial infarction, chronic obstructive pulmonary disease and acute radiation syndrome. It’s a potential wonder-drug built on a the premise that viable adult mesenchymal stem cells (MSCs) can engraft and selectively differentiate, based on the tissue environment, to such lineages as muscle, bone, cartilage, marrow stroma, tendon and fat.
Research shows that MSCs offer anti-inflammatory, anti-fibrotic and regenerative properties that make this platform an exciting disease modulator treatment engine for discovering new drugs. Investors can pick up one share of Osiris for just over $17 per share.
is the company that is doing those adult stem cell trials for Crohn's diseaseI have heard that many people who participated in the trials reported excellent results. The people who had no improvement assumed they were on the placebo. All the Crohnie's are looking forward to furthing testing and availability of this treatment. The alternative for serious Crohn's is biologic treatments like Humira, and they appear to have a cancer risk associated with them.
Finding the next big thing is certainly something biotech investors are always in searching for. Above we discussed our enthusiasm for antisense technology as powerful drug discovery engine. Perhaps the only other discovery platform that provides as much enthusiasm as antisense is stem cells. The leading stem cell company is Osiris Therapeutics (OSIR).
Osiris is developing Prochymal, an adult stem cell product currently in 3 phase III trials for steroid refractory graft-vs-host disease (GvHD), acute GvHD and Crohn’s disease. Prochymal is also in a slew of earlier-stage clinical programs for diabetes, myocardial infarction, chronic obstructive pulmonary disease and acute radiation syndrome. It’s a potential wonder-drug built on a the premise that viable adult mesenchymal stem cells (MSCs) can engraft and selectively differentiate, based on the tissue environment, to such lineages as muscle, bone, cartilage, marrow stroma, tendon and fat.
Research shows that MSCs offer anti-inflammatory, anti-fibrotic and regenerative properties that make this platform an exciting disease modulator treatment engine for discovering new drugs. Investors can pick up one share of Osiris for just over $17 per share.
is the company that is doing those adult stem cell trials for Crohn's diseaseI have heard that many people who participated in the trials reported excellent results. The people who had no improvement assumed they were on the placebo. All the Crohnie's are looking forward to furthing testing and availability of this treatment. The alternative for serious Crohn's is biologic treatments like Humira, and they appear to have a cancer risk associated with them.
